ホーム>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Sodium Channel>>PF-06649298

PF-06649298

カタログ番号GC66038

PF-06649298 は、ナトリウム結合クエン酸トランスポーター (NaCT または SLC13A5) 阻害剤です。 PF-06649298 は、16.2 μ の IC50 値で NaCT と特異的に相互作用し、ヒト肝細胞におけるクエン酸の輸送を阻害します。 PF-06649298 は、糖代謝と脂質代謝の調節の研究に使用できます。

Products are for research use only. Not for human use. We do not sell to patients.

PF-06649298 化学構造

Cas No.: 1854061-16-7

サイズ 価格 在庫数 個数
10mg
$720.00
在庫あり
25mg
$1,485.00
在庫あり
50mg
$2,295.00
在庫あり
100mg
$3,420.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IC50: 408 nM (citrate uptake in HEKNaCT), 16.2 μM (citrate uptake in Human Heps), 4.5 μM (citrate uptake in Mouse Heps), ??100 μM (citrate uptake in HEKNaCD1), ??100 μM (citrate uptake in HEKNaCD3)[1][2]

PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism[1][2].

PF-06649298 (0-100 μM; 30 min) inhibits citrate uptaken in cells[1].

Cell Viability Assay[1]

Cell Line: HEK-293 cells expressing NaCT, NaDC1 or NaDC3, human hepatocytes and mouse epatocytes
Concentration: 0-100 μM
Incubation Time: 30 min
Result: Showed a selectivity for NaCT over the dicarboxylate transporters NaDC1 and NaDC3. Inhibited citrate uptake in HEK-293 cells expressing NaCT, NaDC1 or NaDC3, human hepatocytes and mouse epatocytes with IC50s of 408 nM, ??100 μM, ??100 μM, 16.2 μM and 4.5 μM, respectively.

PF-06649298 (250 mg/kg; p.o. twice a day; for 21 days) reverses glucose intolerance of high fat diet (HFD) mice[2].

Animal Model: Mice with high fat diet (HFD) administration[2]
Dosage: 250 mg/kg
Administration: Oral gavage; 250mg/kg twice a day; for 21 days
Result: Decreased plasma glucose, hepatic triglycerides, diacylglycerides, and acyl-carnitines concentration of livers in HFD mice. Totally reversed glucose intolerance of HFD mice.

レビュー

Review for PF-06649298

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF-06649298

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.